Dose-Survival in SVZ and SGZ of patients with Glioma

Irradiation of the Subventricular Zone and Subgranular Zone: an Atlas-based analysis on Overall Survival in High- and Low-Grade Glioma Patients

Danique E. Bruil B.Sc.¹, Szabolcs David Ph.D.¹, Steven H.J Nagtegaal M.D.¹, Sophia F.A.M de Sonnaville M.D.², Joost J.C. Verhoeff M.D. Ph.D.¹

¹ Department of Radiation Oncology, University Medical Center Utrecht, The Netherlands HP Q 00.3.11 PO box 85500 3508 GA Utrecht, the Netherlands

 ²Department of Neurosurgery, University Medical Center Utrecht, The Netherlands HP G 03.129 PO box 85500 3508 GA Utrecht, the Netherlands

Corresponding author:

Joost J.C. Verhoeff M.D. Ph.D. HP Q 00.3.11 PO box 85500 3508 GA Utrecht, the Netherlands j.j.c.verhoeff-10@umcutrecht.nl

Funding

None.

Conflict of Interest

None.

Authorship

Concept: DEB, SD, SHJN, JJCV Writing: DEB, SD, SHJN, SFAMdS, JJCV Data processing: DEB, SD Statistics: DEB, SHJN Revision: SD, SHJN, SFAMdS, JJCV

All authors have seen and approved the manuscript.

Manuscript word count, including abstract, text, references and figure legends: 5849

Dose-Survival in SVZ and SGZ of patients with Glioma

1 Abstract

2	Background: Neural stem cells in the subventricular- (SVZ) and subgranular zone (SGZ) are hypothesized
3	to support growth of glioma. Therefore, irradiation of the SVZ and SGZ might reduce tumor growth and
4	might improve overall survival (OS). However, it may also inhibit the repair capacity of brain tissue. The
5	aim of this retrospective cohort study is to assess the impact of SVZ and SGZ radiotherapy doses on OS of
6	patients with high-grade (HGG) or low-grade (LGG) glioma.
7	Methods: We included 273 glioma patients who received radiotherapy. We created an SVZ atlas, shared
8	openly with this work, while SGZ labels were taken from the CoBRA atlas. Next, SVZ and SGZ regions were
9	automatically delineated on T1 MR-images. Dose and OS correlations were investigated with Cox
10	regression and Kaplan-Meier analysis.
11	Results: Cox regression analyses showed significant hazard ratios for SVZ dose (univariate: 1.029/Gy,
12	<i>p<0.001</i> ; multivariate: 1.103/Gy, <i>p</i> = 0.002) and SGZ dose (univariate: 1.023/Gy, <i>p<0.001</i> ; multivariate:
13	1.055/Gy, p<0.001) in HGG patients. Kaplan-Meier analysis showed significant correlations between OS
14	and high/low dose groups for HGG patients (SVZ: respectively 10.7 months (>30.33 Gy) vs 14.0 months
15	(<30.33 Gy) median OS, <i>p</i> = 0.011; SGZ: respectively 10.7 months (>29.11 Gy) vs 15.5 months (<29.11 Gy)
16	median OS, <i>p<0.001</i>). No correlations between dose and OS were not found for LGG patients.
17	Conclusion: Irradiation doses on neurogenic areas correlate negatively with OS in patients with HGG.
18	Whether sparing of the SVZ and SGZ during radiotherapy improves OS, should be subject of prospective
10	atualian

19 studies.

2

Dose-Survival in SVZ and SGZ of patients with Glioma

20 Keywords

- 21 Radiotherapy; Glioma; Subventricular Zone; Subgranular Zone; Overall Survival
- 22

23 Key Points

- Neural stem cells in the SVZ and SGZ are hypothesized to support growth of glioma.
- Higher radiation doses on the SVZ and SGZ correlate with lower OS in HGG patients.
- Avoidance of neurogenic niches should be considered to improve OS of HGG patients.
- 27

28 Importance of Study

29 Survival rates and quality of life of patients with glioma are still suboptimal, therefore improvement of 30 radiation treatment planning and delivery is required. The SVZ and SGZ of the adult human brain are a 31 source of brain tissue repair but may also be the source of glioma growth enhancement. By investigating 32 the effects of radiotherapy on SVZ and SGZ, we gain insight into associations between tumor progression and survival. We included 273 adult patients with high- and low- grade glioma who received radiation 33 34 treatment. We found that irradiation doses on neurogenic areas correlate with lower OS in patients with 35 HGG. Avoidance of SVZ and SGZ should be considered to improve OS. These study results will contribute 36 to optimization of brain tumor radiotherapy, focused on increasing OS. In order to facilitate future 37 research into the role of the SVZ, we also provide stereotaxic standard space atlas labels for SVZ and SGZ.

38

39 Abbreviations

40 CAT = Computational Anatomy Toolbox; CI = Confidence interval; CT = Chemotherapy; CTV = Clinical target
41 volume; DG = Dentate gyrus; FH = Frontal horn; GTV = Gross tumor volume; HGG = High-grade glioma;
42 HPC = hippocampus; HR = Hazard ratio; IDH = Isocitrate dehydrogenase; IQR = Interquartile range; KPS =
43 Karnofsky Performance Score; LGG = Low-grade glioma; MGMT = O6-Methylguanine methyltransferase;

- 44 NSC = Neural stem cell; OH = Occipital horn; OS = Overall survival; PFS = Progression-free survival; PTV =
- 45 planning target volume; RT = radiotherapy; SGZ = Subgranular zone; SPM = Statistical Parametric Mapping;
- 46 SVZ = Subventricular zone; TH = Temporal horn; TSE = Turbo Spin Echo; VBG = Virtual Brain Grafting

Dose-Survival in SVZ and SGZ of patients with Glioma

47 Introduction

Glioma is the most common primary brain tumor, and it consists of glial cells which normally support the 48 49 functioning of nerve cells.^{1,2} Survival rates in glioma patients depend on several clinical factors, such as 50 tumor progression and WHO grade. Patients with low-grade glioma (LGG; WHO grade I and II) have a 51 median survival of 5.6 to 11.6 years, while patients with high-grade glioma (HGG; WHO grade III and IV) 52 have a median survival of 14 months to 3.5 years and almost always develop recurrences.³ Current clinical management consists of a combination of different concurrent and consecutive treatments: tumor 53 resection, radiotherapy (RT) and chemotherapy (CT), to reduce tumor size and inhibit progression.^{2,4} To 54 increase survival rate and quality of life of patients with glioma, it is essential to further improve current 55 treatment modalities and investigate the effects of modulating radiation dose to presumed tumor 56 57 supporting brain regions.

58 Recent studies have shown that the growth of glioma might be supported by cells originating from the 59 subventricular zone (SVZ), providing the tumor with neural stem cells (NSCs) and progenitor cells.^{5–7} Lee 60 et al. have shown that neural tissue of HGG patients have NSCs in the SVZ that contain similar driver mutations as their matching glioma, which can migrate and result in progression of HGG.⁵ Others found 61 62 that anatomical contact of the tumor with the SVZ correlates with lower survival rates in both HGG and LGG glioma, independent of other prognostic factors.^{6–8} The SVZ, which is located along the lateral wall of 63 64 the ventricles, is one of the neurogenic niches in the brain, next to the subgranular zone (SGZ) in the dentate gyrus (DG) of the hippocampus (HPC).⁹⁻¹¹ The main role of these niches is neurogenesis, through 65 the generation of multipotent NSCs from the embryonic stage throughout adulthood.⁹⁻¹¹ The SVZ has 66 been shown to play a role in tissue repair and prevention of neurodegenerative diseases,^{12,13} while the 67 SGZ generates NSCs that are involved in pathways of learning and memory.^{9,14} In contrast to NSCs from 68 the SVZ, NSCs in the SGZ are thought unlikely to support glioma development.¹⁵ It has been shown that 69 70 irradiation of the SGZ can result in cognitive decline in patients with central nervous system

Dose-Survival in SVZ and SGZ of patients with Glioma

71	malignancies ¹⁶ , which is associated with lower overall survival (OS). ^{17,18} Studies which investigated
72	irradiation of the SVZ on the other hand, showed that HGG patients who received a high irradiation dose
73	(>40 Gy) on the SVZ have improved OS and Progression-free Survival (PFS), compared to patients that
74	receive a low irradiation dose on the SVZ. ^{19–23} These findings suggest that for HGG, the SVZ should be
75	targeted with high dose during RT to decrease tumor regrowth, while the SGZ might need to be spared to
76	prevent cognitive decline. Contradictory, irradiating the SVZ and therefore damaging its repair capacity
77	for normal brain tissue as well, may lead to opposing effects on OS as previous studies show.
78	The goal of this retrospective cohort study is to determine whether irradiation of the SVZ and SGZ in
79	patients with HGG and LGG will increase survival, by comparing OS of these cohorts to irradiation doses
80	applied to the SVZ and SGZ. By investigating the effects of radiotherapy to SVZ and SGZ in glioma patients,

81 clues for further treatment optimization in the neuro-oncology field may be provided.

Dose-Survival in SVZ and SGZ of patients with Glioma

82 Materials and Methods

83 Patient selection and data collection

84 Patients diagnosed with glioma who received RT between November 2014 and July 2020 at the 85 Department of Radiation Oncology of the UMC Utrecht were retrospectively selected. T1-weighted MR 86 images without contrast enhancement and CT images with mapped radiation dose were collected for 87 every patient. Gross tumor volume (GTV), clinical target volume (CTV) and planning target volume (PTV) 88 were defined by a radiation oncologist as part of routine clinical care. Next, we collected clinical prognostic 89 data, which includes age, sex, Karnofsky Performance Score (KPS), date of last follow-up, date of death, RT start date, survival time, RT dose, RT fractions, total intracranial volume calculated from T1 scans, 90 91 (extent of) resection, (type of) CT and distance between SVZ or the HPC and GTV. The dataset also includes 92 WHO grade and molecular markers of prognosis: isocitrate dehydrogenase (IDH)-mutation status, O6methylguanine methyltransferase (MGMT) methylation status and 1P/19Q-codeletion status.²⁴⁻²⁷ 93 94 Inclusion criteria for constructing the dataset were: patients diagnosed with glioma, receiving cranial RT 95 between November 2014 and July 2020, age \geq 18 years, and accessible planning and dosimetry data. 96 Exclusion criteria were: rare cancer type or disease, re-irradiation and whole-brain radiotherapy. Patients 97 with WHO-grade I/II and WHO-grade III/IV glioma were investigated separately as LGG and HGG cohorts, respectively. Informed consent for this retrospective study was waived by our institutional review board 98 99 (#18/274).

100

101 Image Acquisition

MR images were acquired on a 3T Philips Ingenia scanner (Philips Healthcare, Best, The Netherlands) as part of routine clinical care. T1-weighted MR images were acquired with a 3D turbo-spin echo (TSE) sequence without contrast enhancement, with the following parameters: TR = 8.1 ms, TE = 3.7 ms, flip angle = 8°, 213 continuous axial slices without gap, matrix: 207 x 289, voxel resolution 1 ×0.96×0.96mm.

Dose-Survival in SVZ and SGZ of patients with Glioma

The planning CT scans were acquired on a Brilliance Big bore scanner (Philips Medical Systems, Best, The
Netherlands), with a tube potential of 120 kVp, using a matrix size of 512 × 512 and 0.65 × 0.65 × 3.0 mm
voxel size.

109

110 Image processing and segmentation

All imaging data was processed with FSL,²⁸ Statistical Parametric Mapping (SPM),²⁹ Computational 111 Anatomy Toolbox (CAT12)³⁰ and Virtual Brain Grafting (VBG).³¹ Image processing was done according to 112 our previously published criteria.³² More detailed methods can be found in Supplementary Material 113 Appendix 1. The SGZ masks were acquired via nonlinear registration of the Hippocampus and Subfields 114 CoBrA atlas by Winterburn et al.³³ using the CAT12 toolbox.³⁰ Previously conducted studies acquired SVZ 115 116 labels via manual delineation with varying definitions. In order to facilitate the production and 117 reproducibility of similar research, we developed an SVZ atlas, defined in the symmetric 0.5x0.5x0.5 mm³ 118 MNI-ICBM 152 space (Montreal Neurological Institute-International Consortium for Brain Mapping 119 template created from 152 healthy brain).^{34–36} The atlas is substantiated by the neuro-anatomic 120 development of the SVZ and divided in 4 subregions by the supervision of a neuro-pathologist. Figure 1 121 shows a visual overview of the SVZ and its subregions, along with the HPC and its subregions, as well as the fornix. Details on the defining process of the SVZ atlas are available in Supplementary Material 122 123 Appendix 2.

124

125 <u>Statistical analyses</u>

Data analysis was performed using IBM SPSS (for Windows, version 26.0.0.1). As mentioned before, the primary outcome of this study was OS, defined as months after the first RT session until date of death or last follow-up. Patients that were alive at time of their last follow-up, are censored at the follow-up date.

8

129	The relationship between the mean dose on neurogenic subregions and OS was examined using the Cox
130	Proportional Hazards model ³⁷ and the Kaplan-Meier estimator ³⁸ . Cox Proportional Hazard models were
131	performed with the log partial likelihood ratio test, to calculate the hazard ratios. They were executed
132	both with and without correcting for the following prognostic factors: age, sex, KPS, total intracranial
133	volume, mutations, surgery-extent, CT, SVZ/GTV contact and HPC/GTV contact. For the Kaplan-Meier
134	analysis, patients were dichotomized in two groups based on the median of the mean dose for each
135	neurogenic structure. This resulted in a high-dose group (patients that received greater than the median
136	dose) and a low-dose group (patients that received lower than the median dose). Kaplan-Meier survival
137	curves were compared with the log-rank test. Significance was set at <i>p</i> <0.05 and the confidence interval
138	(CI) was set at 95%. Moreover, Kaplan-Meier survival analysis was performed for GTV contact with the
139	SVZ or HPC, using the same methods as Berendsen et al., Liu et al. and Chiang et al. $^{6-8}$

Dose-Survival in SVZ and SGZ of patients with Glioma

140 Results

141 Participants

142 From all 338 patients that received RT between November 2014 and July 2020, a subset of 273 patients 143 met the inclusion criteria and was selected for analysis. 32 patients were excluded due to re-irradiation 144 and 33 patients were excluded because one or more items were inaccessible or incomplete: planning, 145 delineation and/or dosimetry data. The remaining 273 patients were split up into HGG (n = 226) and LGG 146 patients (n = 47). As expected, the LGG patient group did not include WHO grade I pathologies, therefore 147 the cohort only contained WHO grade II glioma patients. The patient inclusion flowchart is shown in Figure 148 2. Baseline patient and treatment characteristics are shown in Table 1. In our cohort, the median OS from 149 onset of radiotherapy of HGG patients was 12.1 months and median OS of LGG patients was 35.2 months. 150 Median age of the HGG and LGG patients were 63 and 48 year, respectively. Prior to RT, all included 151 patients underwent any form of surgery (biopsy, debulking, resection), and most of them received a 152 partial resection.

153

154 <u>Survival analysis</u>

An overview of Cox regression analyses is shown in Table 2, for each patient cohort separately. For HGG 155 156 patients, univariate analysis resulted in a hazard ratio (HR) of 1.029 per Gy for the mean SVZ dose 157 (p<0.001, [95% Cl 1.013-1.046]) and 1.023 per Gy for the mean SGZ dose (p<0.001, [95% Cl 1.013-1.033]). 158 Multivariate analysis of HGG patient data corrected for age, sex, KPS, total intracranial volume, mutations, 159 CT, surgery-extent and SVZ/HPC contact resulted in a HR of 1.103 (p = 0.002, [95% CI 1.037-1.173]) and 160 1.055 (p<0.001, [95% CI 1.027-1.083]) for the SVZ and SGZ, respectively. Dose on HPC, the occipital horn 161 (OH) of SVZ and temporal horn (TH) of SVZ all showed significant results with an HR >1, while the frontal 162 horn (FH) and SVZ body do not show significant results (Table 2).

Dose-Survival in SVZ and SGZ of patients with Glioma

163	Univariate analysis for LGG patients resulted in a non-significant HR of 1.028 per Gy for mean SVZ dose (p
164	= 0.506, [95% CI 0.948-1.114]) and 1.034 per Gy for mean SGZ dose (p = 0.273, [95% CI 0.974-1.098]).
165	Multivariate analysis of LGG patient data could not be corrected for mutations, as patients with known
166	mutations were still alive at time of data collection. Therefore, we corrected for age, sex, KPS, total
167	intracranial volume, CT, surgery-extent and SVZ/HPC contact. This resulted in an HR of 1.113 ($p = 0.189$,
168	[95% CI 0.949-1.305]) and 1.038 ($p = 0.413$, [95% CI 0.950-1.134]) for mean SVZ and SGZ doses,
169	respectively. Both univariate and multivariate Cox regression analysis did not result in significant
170	outcomes for any neurogenic regions in the LGG patient cohort (Table 2).

171

For Kaplan-Meier analysis, the median of the mean irradiation dose on each neurogenic subregion of the entire glioma patient cohort (HGG + LGG patients) was used as cut-off value for low- and high-dose group divisions (**Table 3**). For the SVZ, this was 30.33 Gy and for the SGZ 29.11 Gy.

HGG patients whose SVZ received high mean SVZ dose showed a significant difference of 3.3 months shorter median OS, compared to patients who received low mean SVZ dose (10.7 months [95% CI 8.6-12.8] vs 14.0 months [95% CI 11.6-16.3] median OS, p = 0.011). In case of the SGZ, HGG patients who received high mean SGZ dose showed a significant decrease of 4.8 months in median OS, compared to patients who received low mean SGZ dose (10.7 months [95% CI 8.8-12.7] vs 15.5 months [95% CI 12.5-18.5] median OS, p < 0.001).

Because the LGG cohort did not reach the proportion of 0.5 survival, median survival estimates could not be calculated and therefore only mean survival estimates are given. The corresponding Kaplan-Meier estimates and curves of SVZ and SGZ doses of both cohorts are shown in **Table 3** and **Figure 3**.

For ipsilateral and contralateral SVZ and SGZ doses, LGG patients did not show any significant OS correlations. HGG patients whose ipsilateral SGZ received high mean ipsilateral SGZ dose (>45.03 Gy), showed a significant difference of 4.8 months shorter OS, compared to patients who received low mean

11

187	ipsilateral SGZ dose (10.7 months [95% CI 8.1-12.5] vs 15.5 months [95% CI 12.5-18.5] median OS, p =
188	0.002). HGG patients whose contralateral SGZ received high mean contralateral SGZ dose (>12.54 Gy),
189	showed a significant decrease of 5.2 months in OS, compared to patients who received low median
190	contralateral SGZ dose (10.6 months [95% CI 9.0-12.3] vs 15.8 months [95% CI 13.1-18.6] median OS, p =
191	0.001). HGG patients whose ipsilateral SVZ received high mean ipsilateral SVZ dose (>39.41 Gy), showed
192	a significant decrease of 2.3 months in OS, compared to patients who received a low mean ipsilateral SVZ
193	dose (11.5 months [95% Cl 9.7-13.4] vs 13.8 months [95% Cl 11.6-16.0] median OS, <i>p</i> = 0.035).
194	HGG patients who had SVZ involvement in the GTV area had a median estimate of 4.3 months less survival
195	compared to patients who do not have contact of the GTV with the SVZ (11.4 months [95% CI 9.7-13.1] vs
196	15.7 months [95% CI 13.5-17.9] median OS, <i>p<0.008</i>). Analyses of SVZ involvement in LGG patients did
197	not result in significant outcomes. We also did not find correlations between HPC contact with GTV and
198	OS, for both HGG and LGG patients.
199	More details and Kaplan-Meier curves of SVZ/HPC – tumor involvement, ipsilateral and contralateral dose
200	analysis and analysis of other neurogenic subregion doses are available in Supplementary material
201	Appendix 3.

Dose-Survival in SVZ and SGZ of patients with Glioma

202 Discussion

203 In this retrospective cohort study, we have tested whether contact between GTV and neurogenic niches 204 and/or irradiation dose to neurogenic niches in the adult human brain are associated with higher OS of patients with HGG and LGG. Neurogenic stem cell areas play a role in the maintenance of healthy brain 205 206 tissue and repair, but may also enhance tumor growth. The hypothesis is based on previous pre-clinical 207 and clinical research which showed that the SVZ might support the growth of LGG and HGG by providing the tumor with NSCs.^{5–8,39} However, it remains controversial, as there is a limited number of previous 208 studies that in contrast report that irradiation of the SVZ decreases OS for patients with HGG.⁴⁰⁻⁴³ A 209 210 preclinical study by Achanta et al. reported a decrease of the proliferating cell marker Ki67 in a mouse model when the SVZ was irradiated,⁴⁴ indicating a deteriorated repair capacity. Studies from Achari et al. 211 212 and Elicin et al. showed dismal effects on OS after high irradiation doses on NSC niches of patients with glioblastoma (n = 61 and n = 60 respectively), 40,43 as did Muracciole et al. and Hallaert et al. reported for 213 214 IDH-wild-type HGG patients (n = 50 and n = 137 respectively).^{41,42} Our study describes this negative 215 correlation between SVZ irradiation and OS in HGG patients as well, involving a large number of patients 216 (n = 226). HGG patients whose SVZ received high mean SVZ dose (>30.33 Gy), showed a significantly decrease of 3.3 months in median OS, compared to patients who received low mean SVZ dose (<30.33 217 Gy). Besides, multivariate Cox regression analysis showed HR's of 1.103 and 1.055 per Gy increasing 218 219 irradiation doses on the SVZ and SGZ, respectively.

220

221 On the contrary, the majority of previous studies in this field shows higher survival rates of HGG patients 222 following irradiation of the SVZ.^{19–23} The prospective study from Malik et al. involving 45 glioblastoma 223 patients showed improved survival when patients receive additional irradiation dose on NSC niches in the 224 ipsilateral hemisphere.⁴⁵ We have investigated ipsilateral and contralateral doses on neurogenic niches as 225 well. Our retrospective outcomes show again that additional irradiation dose on both ipsilateral SVZ or

Dose-Survival in SVZ and SGZ of patients with Glioma

226 SGZ is negatively correlated with OS in HGG patients, contradicting the prospective study from Malik et 227 al. Interestingly, when considering the outcomes of the FH dose in HGG patients, neither univariate or multivariate Cox regression and Kaplan-Meier survival outcomes are significant. This may indicate that 228 229 the FH is an area where the tumor is located more often than in other SVZ areas, which can interfere with 230 the results. However, the incidence of tumor location in the patient population of this study is evenly 231 divided between the SVZ subregions, and is not more common in the FH. This may suggest that the SVZ is 232 not a homogeneous neurogenic region. 233 In contrast to the NSCs from the SVZ, previous research elucidated that NSCs in the SGZ of the HPC are not likely to sustain glioma growth, and that irradiation of the HPC may even result in cognitive decline 234 and lower OS.^{15–18} These results are in line with our findings, where we show that HGG patients who 235 236 received a high mean SGZ dose (>29.11 Gy) show a significant decrease of 4.8 months in median OS,

compared to patients who received a low median SGZ dose (<29.11 Gy).

We investigated the effect of irradiation on the SVZ and SGZ in LGG patients as well. Both the univariate and the multivariate analysis of LGG patients did not result in a significant correlation between irradiation dose on neurogenic niches and OS for LGG patients. This may be due to the relatively small number of patients in our study that were diagnosed with WHO grade II.

242

Furthermore, we show that SVZ contact to the GTV is associated with a 4.3 months lower median OS in HGG patients compared to patients that do not have SVZ contact with the GTV, which is in line with findings by Berendsen et al.⁶ However, we are aware that this may be misleading, as the SVZ is located centrally in the brain and it is suggested that central tumor location itself is associated with worse OS.⁴⁶ We performed similar analyses for LGG patients as well, following methods of Chiang et al.⁸ and Liu et al.⁷ but we did not find a relation between SVZ contact with GTV and survival in this patient group. The outcomes may be due to our LGG patient sample size which is less than half of the sample size used in the

Dose-Survival in SVZ and SGZ of patients with Glioma

study of Liu et al.⁷ Another consideration is the atypical division of WHO grades in high- and low-grade, as
Chiang et al.⁸ included WHO III patients as LGG patients and we included WHO III patients in the HGG
cohort.

253

The dismal survival outcomes by high dose irradiation of neurogenic niches can be explained by the neurotoxic side-effects of irradiation outweighing the positive effects. Lower survival might be caused by the damaging of NSCs in the SVZ and SGZ, leading to decreased repair capacity and results in enhanced neurocognitive impairment, which again is associated with lower OS.¹⁸

258 The strength of our study is the high number of HGG patients included in our analyses in comparison with 259 previous studies, which may support the soundness of our results. Also, the patients that were included 260 received fairly homogeneous treatments, with typically surgery followed by chemoRT and adjuvant CT. 261 Another consideration is the lack of consensus in literature on the delineation of the SVZ, due to lack of 262 existing guidelines and/or caused by irregular manual delineations.⁴⁷ Previous research was performed 263 with different volumes and shapes for the SVZ, causing inconsistency in methodology among studies. In 264 this study, we derived delineations of the SVZ from the open access SVZ atlas in standard MNI space, which now can be used in future research, enabling reproducibility. Moreover, for dichotomization in low 265 266 and high RT dose groups, there is no congruence in literature about a cut-off value for irradiation dose. In 267 addition to dichotomization in low and high RT dose groups for Kaplan-Meier analysis, we chose to include 268 irradiation doses as continuous variables in cox-regression analyses as well, to avoid bias between specific 269 subcategories.⁴⁸

270 Nevertheless, our study shows there is room for improvements as well. First, since we could not collect 271 clinical follow-up data other than death, PFS could not be examined. Besides, we did not assess cognitive 272 performance of the patients, since neuropsychological evaluation was not performed routinely. Another 273 limitation may be the effect of tumor location, because a tumor that is located near the SVZ or SGZ leads

274	to elevated irradiation doses on the SVZ or SGZ as well. As it is suggested that central tumor location is
275	associated with worse OS, ⁴⁶ it may interfere with the results. Therefore, we are aware that we cannot
276	correct our outcomes for tumor location completely. Furthermore, the limited number of LGG patients in
277	our study has probably led to insignificant results on their survival analysis. Finally, our study is of
278	retrospective nature, which might have resulted in selection bias. To validate our results, prospective
279	investigations are required, where irradiation and sparing of the neurogenic niches have to be compared.
280	
281	In conclusion, in this retrospective study we present an SVZ atlas, SVZ delineation guidelines, and results
281 282	In conclusion, in this retrospective study we present an SVZ atlas, SVZ delineation guidelines, and results from a large cohort of patients with HGG, that shows a statistically significant decrease in median OS with
282	from a large cohort of patients with HGG, that shows a statistically significant decrease in median OS with
282 283	from a large cohort of patients with HGG, that shows a statistically significant decrease in median OS with additional increased irradiation dose on the SVZ and SGZ. This suggests that, to improve OS, these
282 283 284	from a large cohort of patients with HGG, that shows a statistically significant decrease in median OS with additional increased irradiation dose on the SVZ and SGZ. This suggests that, to improve OS, these neurogenic niches need to be avoided with radiotherapy in HGG patients. Modern radiotherapy planning

288	Fundir	ng
289	None.	
290		
291	Ackno	wledgements
292	We w	ould like to thank Dr. Angelika Mühlebner (Department of Pathology, UMC Utrecht) for her
293	contril	butions to the SVZ atlas.
294		
295	Refere	ences
296 297	1	Vescovi, Angelo L, Galli, Rossella and Reynolds, Brent A (2006) "Brain tumour stem cells." <i>Nature Reviews Cancer</i> , 6(6), pp. 425–436.
298	2	Reijneveld, J C (2010) "Neuro-oncologie," in <i>Het Neurologie Formularium</i> , Springer, pp. 210–217.
299 300	3	Sizoo, E M, Reijneveld, J C, Lagerwaard, F J, Buter, J, et al. (2010) "Beloop en beleid bij vermoeden van een laaggradig glioom." <i>Nederlands Tijdschrift voor Geneeskunde</i> , 154.
301 302 303	4	Stupp, Roger, Mason, Warren P, van den Bent, Martin J, Weller, Michael, et al. (2005) "Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma." <i>New England</i> <i>journal of medicine</i> , 352(10), pp. 987–996.
304 305 306	5	Lee, Joo Ho, Lee, Jeong Eun, Kahng, Jee Ye, Kim, Se Hoon, et al. (2018) "Human glioblastoma arises from subventricular zone cells with low-level driver mutations." <i>Nature</i> , 560(7717), pp. 243–247.
307 308 309	6	Berendsen, Sharon, van Bodegraven, Emma, Seute, Tatjana, Spliet, Wim G M, et al. (2019) "Adverse prognosis of glioblastoma contacting the subventricular zone: Biological correlates." <i>PloS one</i> , 14(10), p. e0222717.
310 311 312	7	Liu, Shuai, Wang, Yinyan, Fan, Xing, Ma, Jun, et al. (2016) "Anatomical Involvement of the Subventricular Zone Predicts Poor Survival Outcome in Low-Grade Astrocytomas." <i>PLOS ONE</i> , 11(4), p. e0154539.
313 314 315	8	Chiang, Gloria C, Pisapia, David J, Liechty, Benjamin, Magge, Rajiv, et al. (2020) "The Prognostic Value of MRI Subventricular Zone Involvement and Tumor Genetics in Lower Grade Gliomas." <i>Journal of Neuroimaging</i> , 30(6), pp. 901–909.
316 317	9	Zhao, Chunmei, Deng, Wei and Gage, Fred H (2008) "Mechanisms and functional implications of adult neurogenesis." <i>Cell</i> , 132(4), pp. 645–660.


318 319	10	Katsimpardi, Lida and Lledo, Pierre-Marie (2018) "Regulation of neurogenesis in the adult and aging brain." <i>Current opinion in neurobiology</i> , 53, pp. 131–138.
320 321	11	Bond, Allison M, Ming, Guo-li and Song, Hongjun (2015) "Adult mammalian neural stem cells and neurogenesis: five decades later." <i>Cell stem cell</i> , 17(4), pp. 385–395.
322 323	12	Richardson, R Mark, Sun, Dong and Bullock, M Ross (2007) "Neurogenesis after traumatic brain injury." <i>Neurosurgery Clinic</i> s, 18(1), pp. 169–181.
324 325 326	13	Curtis, Maurice A, Faull, Richard L M and Eriksson, Peter S (2007) "The effect of neurodegenerative diseases on the subventricular zone." <i>Nature Reviews Neuroscience</i> , 8(9), pp. 712–723.
327 328 329	14	Deng, Wei, Aimone, James B and Gage, Fred H (2010) "New neurons and new memories: how does adult hippocampal neurogenesis affect learning and memory?" <i>Nature reviews neuroscience</i> , 11(5), pp. 339–350.
330 331 332 333	15	Mistry, Akshitkumar M, Dewan, Michael C, White-Dzuro, Gabrielle A, Brinson, Philip R, et al. (2017) "Decreased survival in glioblastomas is specific to contact with the ventricular- subventricular zone, not subgranular zone or corpus callosum." <i>Journal of neuro-oncology</i> , 132(2), pp. 341–349.
334 335	16	Gondi, Vinai, Tomé, Wolfgang A and Mehta, Minesh P (2010) "Why avoid the hippocampus? A comprehensive review." <i>Radiotherapy and Oncology</i> , 97, pp. 370–376.
336 337	17	Taphoorn, Martin J.B. and Klein, Martin (2004) "Cognitive deficits in adult patients with brain tumours." <i>Lancet Neurology</i> , 3(3), pp. 159–168.
338 339 340	18	Klein, M, Postma, T J, Taphoorn, M J B, Aaronson, N K, et al. (2003) "The prognostic value of cognitive functioning in the survival of patients with high-grade glioma." <i>Neurology</i> , 61(12), pp. 1796–1798.
341 342 343	19	Darázs, Barbara, Ruskó, László, Végváry, Zoltán, Ferenczi, Lehel, et al. (2019) "Subventricular zone volumetric and dosimetric changes during postoperative brain tumor irradiation and its impact on overall survival." <i>Physica Medica</i> , 68, pp. 35–40.
344 345 346 347	20	Chen, Linda, Guerrero-Cazares, Hugo, Ye, Xiaobu, Ford, Eric, et al. (2013) "Increased subventricular zone radiation dose correlates with survival in glioblastoma patients after gross total resection." <i>International Journal of Radiation Oncology* Biology* Physics</i> , 86(4), pp. 616–622.
348 349 350	21	Lee, Percy, Eppinga, Wietse, Lagerwaard, Frank, Cloughesy, Timothy, et al. (2013) "Evaluation of high ipsilateral subventricular zone radiation therapy dose in glioblastoma: a pooled analysis." <i>International Journal of Radiation Oncology* Biology* Physics</i> , 86(4), pp. 609–615.

351 352 353	22	Evers, Patrick, Lee, Percy P, DeMarco, John, Agazaryan, Nzhde, et al. (2010) "Irradiation of the potential cancer stem cell niches in the adult brain improves progression-free survival of patients with malignant glioma." <i>BMC Cancer 2010 10:1</i> , 10(1), pp. 1–7.
354 355 356	23	Gupta, Tejpal, Nair, Vimoj, Paul, Siji Nojin, Kannan, Sadhana, et al. (2012) "Can irradiation of potential cancer stem-cell niche in the subventricular zone influence survival in patients with newly diagnosed glioblastoma?" <i>Journal of Neuro-Oncology 2012 109:1</i> , 109(1), pp. 195–203.
357 358	24	Prognostik, Düflük Evreli Gliomlarda (2008) "Efficacy of prognostic factors on survival in patients with low grade glioma." <i>Turkish neurosurgery</i> , 18(4), pp. 336–344.
359 360 361	25	Thakkar, Jigisha P, Dolecek, Therese A, Horbinski, Craig, Ostrom, Quinn T, et al. (2014) "Epidemiologic and molecular prognostic review of glioblastoma." <i>Cancer Epidemiology and</i> <i>Prevention Biomarkers</i> , 23(10), pp. 1985–1996.
362 363 364	26	Zhao, Ye-Yu, Chen, Si-Hai, Hao, Zheng, Zhu, Hua-Xin, et al. (2019) "A nomogram for predicting individual prognosis of patients with low-grade glioma." <i>World neurosurgery</i> , 130, pp. e605– e612.
365 366	27	Ducray, François, Idbaih, Ahmed, Wang, Xiao-Wei, Cheneau, Caroline, et al. (2011) "Predictive and prognostic factors for gliomas." <i>Expert review of anticancer therapy</i> , 11(5), pp. 781–789.
367 368	28	Jenkinson, Mark, Beckmann, Christian F., Behrens, Timothy E.J., Woolrich, Mark W. and Smith, Stephen M. (2012) "FSL." <i>NeuroImage</i> , 62(2), pp. 782–790.
369 370	29	Penny, William D, Friston, Karl J, Ashburner, John T, Kiebel, Stefan J and Nichols, Thomas E (2011) Statistical parametric mapping: the analysis of functional brain images, Elsevier.
371 372	30	Gaser, C, Hbm, R Dahnke - and 2016, undefined (n.d.) "CAT-a computational anatomy toolbox for the analysis of structural MRI data." <i>neuro.uni-jena.de</i> .
373 374 375	31	Radwan, Ahmed M., Emsell, Louise, Blommaert, Jeroen, Zhylka, Andrey, et al. (2021) "Virtual brain grafting: Enabling whole brain parcellation in the presence of large lesions." <i>NeuroImage</i> , 229, p. 117731.
376 377 378	32	Nagtegaal, Steven H.J., David, Szabolcs, van der Boog, Arthur T.J., Leemans, Alexander and Verhoeff, Joost J.C. (2019) "Changes in cortical thickness and volume after cranial radiation treatment: A systematic review." <i>Radiotherapy and Oncology</i> , 135, pp. 33–42.
379 380 381	33	Winterburn, Julie L., Pruessner, Jens C., Chavez, Sofia, Schira, Mark M., et al. (2013) "A novel in vivo atlas of human hippocampal subfields using high-resolution 3T magnetic resonance imaging." <i>NeuroImage</i> , 74, pp. 254–265.
382 383	34	Fonov, Vladimir, Evans, Alan C., Botteron, Kelly, Almli, C. Robert, et al. (2011) "Unbiased average age-appropriate atlases for pediatric studies." <i>NeuroImage</i> , 54(1), pp. 313–327.

384 385	35	Fonov, VS, Evans, AC, McKinstry, RC, Almli, CR and Collins, DL (2009) "Unbiased nonlinear average age-appropriate brain templates from birth to adulthood." <i>NeuroImage</i> , 47, p. S102.
386 387	36	Atlas, ICBM (2001) "McConnell Brain Imaging Centre." <i>Montréal Neurological Institute, McGill</i> University, Montréal, Canada.
388 389	37	Cox, David R (1972) "Regression models and life-tables." <i>Journal of the Royal Statistical Society:</i> Series B (Methodological), 34(2), pp. 187–202.
390 391	38	Kaplan, Edward L and Meier, Paul (1958) "Nonparametric estimation from incomplete observations." <i>Journal of the American statistical association</i> , 53(282), pp. 457–481.
392 393 394	39	Marsh, James C, Wendt, Julie A, Herskovic, Arnold M, Diaz, Aidnag, et al. (2012) "High-grade glioma relationship to the neural stem cell compartment: a retrospective review of 104 cases." <i>International Journal of Radiation Oncology Biology Physics</i> , 82(2), pp. e159–e165.
395 396	40	Achari, R., Arunsingh, M., Badgami, R. K., Saha, A., et al. (2017) "High-dose Neural Stem Cell Radiation May Not Improve Survival in Glioblastoma." <i>Clinical Oncology</i> , 29(6), pp. 335–343.
397 398 399	41	Muracciole, Xavier, El-Amine, Wassim, Tabouret, Emmeline, Boucekine, Mohamed, et al. (2018) "Negative survival impact of high radiation doses to neural stem cells niches in an IDH-wild-type glioblastoma population." <i>Frontiers in oncology</i> , 8, p. 426.
400 401 402	42	Hallaert, Giorgio, Pinson, Harry, van den Broecke, Caroline, Sweldens, Caroline, et al. (2021) "Survival impact of incidental subventricular zone irradiation in IDH-wildtype glioblastoma." <i>Acta</i> <i>Oncologica</i> , 60(5), pp. 613–619.
403 404 405	43	Elicin, Olgun, Inac, Ebrar, Uzel, Esengul Kocak, Karacam, Songul and Uzel, Omer Erol (2014) "Relationship between survival and increased radiation dose to subventricular zone in glioblastoma is controversial." <i>Journal of neuro-oncology</i> , 118(2), pp. 413–419.
406 407 408	44	Achanta, Pragathi, Capilla-Gonzalez, Vivian, Purger, David, Reyes, Juvenal, et al. (2012) "Subventricular zone localized irradiation affects the generation of proliferating neural precursor cells and the migration of neuroblasts." <i>Stem Cells</i> , 30(11), pp. 2548–2560.
409 410 411	45	Malik, M., Akram, K.S., Joseph, D., Valiyaveettil, D. and Ahmed, S.F. (2015) "Prospective Study of Irradiation of Potential Stem Cell Niches in Glioblastoma." <i>International Journal of Radiation Oncology*Biology*Physics</i> , 93(3), p. S111.
412 413 414	46	Fyllingen, Even Hovig, Bø, Lars Eirik, Reinertsen, Ingerid, Store Jakola, Asgeir, et al. (2021) "Survival of glioblastoma in relation to tumor location: a statistical tumor atlas of a population- based cohort." <i>Acta Neurochirurgica</i> , 163, pp. 1895–1905.
415 416	47	Nourallah, B., Digpal, R., Jena, R. and Watts, C. (2017) "Irradiating the Subventricular Zone in Glioblastoma Patients: Is there a Case for a Clinical Trial?" <i>Clinical Oncology</i> , 29(1), pp. 26–33.

- 417 48 Royston, Patrick, Altman, Douglas G and Sauerbrei, Willi (2006) "Dichotomizing continuous
- 418 predictors in multiple regression: a bad idea." *STATISTICS IN MEDICINE Statist. Med*, 25(1), pp.
- 419 127–141.
- 420
- 421


Dose-Survival in SVZ and SGZ of patients with Glioma



422

Figure 1. The subventricular zone (SVZ) structure (1) and hippocampus (HPC) structure (2) including the subgranular zone (SGZ) within the dentate gyrus (DG) on T1-weighted symmetrical 0.5 mm isotropic resolution template MRI images (ICBM 2009b nonlinear symmetric). A. Coronal view. B. Axial view. C. Sagittal view right. D. Sagittal view left. E. 3D-model of the structures, shown from the left sagittal view.

Dose-Survival in SVZ and SGZ of patients with Glioma



427

- 428 **Figure 2.** Flowchart of patient selection and overview of in- and exclusion criteria. **A.** In- and exclusion
- 429 criteria for patient selection. **B.** Flowchart of glioma patient selection, divided in high-grade glioma (HGG)
- 430 and low-grade glioma (LGG) patient cohorts. *RT* radiotherapy.




Figure 3. Overall survival (OS) curves for high- and low-dose groups, stratified by the median of the mean subventricular zone (SVZ) dose (A and C) and the median of the mean subgranular zone (SGZ) dose (B and D). **A.** OS curve of the proportion of high-grade glioma (HGG) patients relative to the median SVZ dose (*p* = 0.005, log-rank test). **B.** OS curve of the proportion of HGG patients relative to the median SGZ dose (*p*<0.001, log-rank test). **C.** OS curve of the proportion of low-grade glioma (LGG) patients relative to the median SVZ dose (*p* = 0.395, log-rank test). **D.** OS curve of the proportion of LGG patients relative to the median SGZ dose (*p* = 0.190, log-rank test).

Dose-Survival in SVZ and SGZ of patients with Glioma

- 439 Table 1. Baseline patient and treatment characteristics of high-grade glioma (HGG) patients and low-grade
- 440 glioma (LGG) patients.

Characteristics	HGG	LGG
Patient count (%)	226 (100)	47 (100)
Median age in years (IQR)	63 (55-70)	48 (37-59)
Sex		
Female (%)	79 (35)	16 (34)
Male (%)	147 (65)	31 (66)
Median KPS (IQR)	80 (70-80)	90 (80-90)
Total intracranial volume in cm3 (IQR)	1540 (1424-1632)	1478 (1413-1666)
Extent of surgery		
Biopsy (%)	53 (23.5)	10 (21.3)
Partial resection (%)	117 (51.8)	31 (66)
Complete resection (%)	56 (24.8)	6 (12.8)
Chemotherapy		
No (%)	42 (18.6)	6 (12.8)
Yes (%)	184 (81.4)	41 (87.2)
Type of chemotherapy	, , , , , , , , , , , , , , , , , , ,	
Temozolomide (%)	178 (96.7)	29 (70.7)
Lomustine (%)	1 (0.5)	0 (0.0)
PCV (%)	5 (2.7)	12 (29.3)
GTV – SVZ contact	. ,	. ,
No (%)	50 (22.1)	12 (25.5)
Yes (%)	176 (77.9)	35 (74.5)
GTV – HPC contact	, , , , , , , , , , , , , , , , , , ,	, , , , , , , , , , , , , , , , , , ,
No (%)	139 (61.5)	22 (46.8)
Yes (%)	87 (38.5)	25 (53.2)
MGMT methylation		. ,
No (%)	95 (42)	3 (6.4)
Yes (%)	47 (20.8)	1 (2.1)
Unknown (%)	84 (37.2)	43 (91.5)
IDH mutation	- (-)	- ()
No (%)	208 (92)	10 (21.3)
Yes (%)	14 (6.2)	33 (70.2)
Unknown (%)	4 (1.8)	4 (8.5)
1P/19Q codeletion	· - /	<u> </u>
No (%)	105 (46.5)	18 (38.3)
Yes (%)	9 (4)	13 (27.7)
Unknown (%)	112 (49.6)	16 (34)

441 IQR Interquartile range, PCV Procarbazine Lomustine Vincristine, SVZ Subventricular zone, HPC

442 Hippocampus, *MGMT* O6-methylguanine methyltransferase, *IDH* Isocitrate dehydrogenase.

Dose-Survival in SVZ and SGZ of patients with Glioma

- 443 **Table 2.** Cox regression analysis of subregion doses on overall survival (OS) in patients with high-grade
- 444 glioma (HGG) and low-grade glioma (LGG). Analyses were performed univariate for irradiation dose only,
- and multivariate corrected for mentioned different covariates*.

Patient	Subregion	Univariable		Multivariable*		
diagnosis		HR (95% CI)	p-value	HR (95% CI)	p-value	
High-grade	НРС	1.023 (1.013-1.032)	<0.001	1.054 (1.026-1.083)	<0.001	
glioma	SGZ	1.023 (1.012-1.033)	<0.001	1.055 (1.027-1.083)	<0.001	
	SVZ	1.029 (1.013-1.046)	<0.001	1.103 (1.037-1.173)	0.002	
	FH	1.017 (1.004-1.030)	0.901	0.996 (0.974-1.018)	0.707	
	Body	1.017 (1.004-1.030)	0.008	1.011 (0.968-1.056)	0.612	
	ОН	1.024 (1.013-1.034)	<0.001	1.043 (1.018-1.068)	0.001	
	тн	1.024 (1.013-1.034)	<0.001	1.056 (1.025-1.088)	<0.001	
	*Age, Sex, KPS, t	. KPS, total intracranial volume, MGMT, IDH, 1P/19Q deletion, CT, Surgery				
	extent, GTV-SVZ	Z contact or GTV-HPC contact (For the SVZ: GTV-SVZ contact, for the				
	SGZ: GTV-SGZ co	ntact)				
Low-grade	НРС	1.033 (0.971-1.098)	0.331	1.036 (0.947-1.132)	0.441	
glioma	SGZ	1.034 (0.974-1.098)	0.273	1.038 (0.950-1.134)	0.413	
	SVZ	1.028 (0.948-1.114)	0.506	1.113 (0.949-1.305)	0.189	
	FH	1.026 (0.957-1.100)	0.470	1.097 (0.982-1.226)	0.102	
	Body	1.002 (0.941-1.066)	0.962	1.041 (0.941-1.139)	0.385	
	ОН	1.021 (0.963-1.082)	0.492	1.014 (0.920-1.117)	0.781	
	тн	1.030 (0.969-1.095)	0.343	1.013 (0.935-1.097)	0.749	
	* Age, Sex, KPS, total intracranial volume, CT, Surgery-extent, GTV-SVZ contact or GTV-					
	HPC contact (For the SVZ: GTV-SVZ contact, for the SGZ: GTV-SGZ contact)					

446 *MGMT* O6-methylguanine methyltransferase, *IDH* Isocitrate dehydrogenase, *HPC* Hippocampus, *SGZ* 447 Subgranular zone, *SVZ* Subventricular zone, *FH* Frontal horn, *OH* Occipital horn, *TH* Temporal horn, *HR*

448 Hazard ratio of overall survival, *CI* Confidence interval.

Dose-Survival in SVZ and SGZ of patients with Glioma

- 449 **Table 3.** Overview of the median irradiation dose received by each neurogenic subregion and Kaplan-
- 450 Meier analysis of subregion doses on overall survival (OS), with median estimates for the high-grade
- 451 glioma (HGG) group, and mean estimates for low-grade glioma (LGG) patients. Estimates are given in
- 452 months.

Patient	Subregion	Median	Dose group	Median OS estimate (95%	p-value
diagnosis		dose (Gy)		CI)	
High-grade glioma	НРС	29.30	High (>29.30)	10.7 (8.6-12.7)	<0.001
			Low (<29.30)	15.7 (12.8-18.7)	
	SGZ	29.11	High (>29.11)	10.7 (8.8-12.7)	<0.001
			Low (<29.11)	15.5 (12.5-18.5)	
	SVZ	30.33	High (>30.33)	10.7 (8.6-12.8)	0.011
			Low (<30.33)	14.0 (11.6-16.3)	
	FH	34.63	High (>34.63)	13.5 (9.9-17.1)	0.830
			Low (<34.63)	12.6 (11.6-13.5)	
	Body	35.34	High (>35.34)	10.0 (8.2-11.9)	0.033
			Low (<35.34)	17.1 (11.9-16.0)	
	ОН	27.92	High (>27.92)	10.0 (8.5-11.4)	<0.001
			Low (<27.92)	17.1 (14.6-19.7)	
	T 11	H 26.95	High (>26.95)	10.8 (9.3-12.3)	<0.001
	10		Low (<26.95)	15.7 (10.9-20.4)	
				Mean OS estimate (95% CI)	
Low-grade glioma	НРС	29.30	High (>29.30)	54.4 (43.0-64.8)	0.314
			Low (<29.30)	60.3 (54.9-65.6)	
	SGZ	29.11	High (>29.11)	53.0 (40.8-65.3)	0.190
			Low (<29.11)	60.5 (55.4-65.6)	
	svz	30.33	High (>30.33)	53.8 (41.0-66.5)	0.395
			Low (<30.33)	52.5 (48.6-56.4)	
	FH	34.63	High (>34.63)	58.8 (51.9-65.7)	0.766
			Low (<34.63)	50.3 (44.3-56.4)	
	Body	35.34	High (>35.34)	57.6 (46.0-69.2)	0.988
			Low (<35.34)	51.2 (46.8-55.7)	
	ОН	27.92	High (>27.92)	49.7 (36.2-63.1)	0.329
			Low (<27.92)	59.6 (54.4-64.8)	
	тн	26.95	High (>26.95)	50.2 (38.5-61.8)	0.316
			Low (<26.95)	59.5 (54.2-64.8)	

453 *HPC* Hippocampus, *SGZ* Subgranular zone, *SVZ* Subventricular zone, *FH* Frontal horn, *OH* Occipital horn,
 454 *TH* Temporal horn, *OS* overall survival, *CI* Confidence interval.